Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide - AstraZeneca

Drug Profile

Exenatide - AstraZeneca

Alternative Names: AC 2993; AC002993; AC2993A; Byetta; Exendin 4; LY2148568

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Radboud University; Regional and University Hospital of Besancon
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Metabolic disorders; Type 1 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 01 Mar 2022 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents) in Brazil, Philippines, South Africa, Russia, USA, Mexico, India and South Korea (SC)
  • 04 Jun 2020 AstraZeneca withdraws planned phase I trial in Type-2 diabetes mellitus in China, prior to enrollment initiations due to strategic considerations (NCT04001231)
  • 01 Apr 2020 Astrazeneca completes a phase III trial in Type 2 diabetes mellitus (Adjunctive treatment, In adolescents) in USA, Mexico, South Korea, India, South Africa, Russia, Philippines and Brazil (SC) (NCT00658021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top